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Abstract
Purpose This study used an empirical approach to iden-
tify and validate the classification of patients with schizo-
phrenia in ‘‘good,’’ ‘‘moderate,’’ or ‘‘poor’’ functioning
groups based on the assessment of functional measures.
Methods Using data from a study of schizophrenia out-
patients, patients were classified into functional groups
using cluster analysis based on the Heinrich–Carpenter
Quality of Life Scale (QLS), the 36-item Short-Form
Health Survey (SF-36) Mental Component Summary
Score, and a productivity measure. A three-cluster solution
was chosen. Concurrent, convergent, and discriminant
validity were assessed. Criteria for classifying patient
functioning as ‘‘good,’’ ‘‘moderate,’’ or ‘‘poor’’ were estab-
lished using classification and regression tree analysis.
Results The three clusters consistently differentiated patients
on the QLS, SF-36 Mental Component Summary Score, and
productivity measure. The clusters also differed on other
functional measures and were concordant with previous func-
tional classifications. Concurrent, convergent, and discrimi-
nant validity were good. ‘‘Good’’ functioning was identified as a
QLS total score C84.5; ‘‘moderate’’ and ‘‘poor’’ functioning
were separated by a cutoff score of 15.5 on the QLS intrapsy-
chic foundation domain. Sensitivity ranged from 86 to 93 %
and specificity from 89 to 99 %.
Conclusions The heterogeneity in functioning of schizo-
phrenia patients can be classified reliably in an empirical
manner using specific cutoff scores on commonly used
functional measures.
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Abbreviations
CART Classification and regression tree
EQ-5D EuroQol-5 Dimensions Questionnaire
PANSS Positive and Negative Symptom Scale
QLS Quality of Life Scale
SF-36 Medical Outcomes Study Short Form-36
SOFI Schizophrenia Objective Functioning Scale
SD Standard deviation
VAS Visual analogue scale
Introduction
Schizophrenia is often a severe and persistent mental ill-
ness typically accompanied by functional impairment and
disability [1], characterized by poor psychosocial func-
tioning, difficulties in activities of daily living and inter-
personal relationships, low levels of productivity, and high
rates of unemployment [2–4]. There is marked heteroge-
neity in the level of psychosocial functioning among
patients with schizophrenia; some patients can function
with mild difficulties, while others are severely impaired
and unable to live independently.
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A number of instruments have been developed in the
field of schizophrenia research to assess the patients’
health-related quality of life to help clinicians and
researchers better assess patients’ health and function.
However, lack of a gold standard with which to compare
instrument-based scores has limited their usefulness [5]. At
present, the health-related quality of life instrument used
most frequently in schizophrenia research is the Heinrich–
Carpenter Quality of Life in Schizophrenia Scale (QLS)
[6], a clinician-rated scale of patients’ social, occupational,
and psychological functioning. Interestingly, despite the
extensive use of the QLS in schizophrenia research, the
interpretation of QLS scores has rarely been studied. While
higher scores indicate better functioning of schizophrenia
patients, there are no studies empirically delineating spe-
cific cutoff scores that correspond to various levels of
functioning. The QLS is not alone, as the interpretability
of other health status assessment tools in the treatment of
schizophrenia has rarely been a topic of investigation. To
our knowledge, the only previous attempt to empirically
interpret scores of a health status measure in schizophrenia
was made by Cramer et al. [7] who studied the QLS and
identified that ‘‘improved’’ status corresponds to 26 percent
increase in QLS scores and ‘‘much better’’ status is asso-
ciated with a 50 percent increase in QLS scores. That study
determined the average magnitude of change in QLS scores
that is associated with clinician-detected improvement or
deterioration, thus clarifying the meaning of a clinically
detectable improvement, but it does not enable clinicians
and schizophrenia researchers to identify what a specific
QLS score may mean, because a patient may be ‘‘much
improved’’ but still exhibit a relatively poor level of
functioning. At present, it is unclear which QLS scores
reflect a patient’s level of functioning as ‘‘good,’’ ‘‘mod-
erate,’’ or ‘‘poor,’’ and no cutoff scores have been yet
delineated to identify each functional level category. A few
previous attempts have been made to classify schizophre-
nia patient functioning according to severity level [8, 9],
but none have used an empirically driven approach that
focused only on functioning. While Lipkovich et al. [8]
created a data-driven classification that combined symp-
tomatology and functioning using the QLS and the Positive
and Negative Syndrome Scale [10], Stahl et al. [9] used
theoretically based criteria to classify patients using the
QLS. Previous research has shown that there remains a
need for a data-driven classification based on measures of
functioning. Classification of schizophrenia patients into
distinct levels of functioning may be useful for translating
absolute scale scores into meaningful and relevant cate-
gories, facilitating interpretation of the scores in clinical
practice and schizophrenia research. Thus, the identifica-
tion of categories may facilitate comparison among studies
and the translation of the evaluation of the patient into
terms that can be easily communicated to the patients and
their families. The primary objective of this analysis was to
identify, using an empirical approach, the equivalence of
‘‘good,’’ ‘‘moderate,’’ and ‘‘poor’’ levels of functioning on
various functional measures. A secondary objective was to
assess the construct validity of the new functional category
scores in the treatment of outpatients with schizophrenia.
We hypothesized that compared to patients with ‘‘poor’’ or
‘‘moderate’’ levels of functioning on the QLS, those with
‘‘good’’ functional levels will exhibit lower schizophrenia
symptom severity levels, greater levels of productive
activity, and higher scores on other health-related quality
of life (QOL) measures, including patient self-reported
scales like the SF-36 and EQ-5D and clinician-rated scales
like the schizophrenia objective functioning instrument
(SOFI). We also hypothesized that differentiation between
patients’ levels of functioning on the QLS will be best
accomplished not only by the total score on the scale, but
also that patients’ drive, sense of purpose, and motivation
(measured in the QLS by the intrapsychic domain) will
play an important role, more so than other domains, as
patients’ drive and initiative were found to be robust pre-
dictors of overall QOL, as measured by QLS, than actual
accomplishments and satisfaction [11].
Patients and methods
Study design and patient population
This analysis used baseline data from a 2-year multicenter,
randomized, open-label study comparing the long-term
treatment effectiveness and safety of olanzapine long-
acting injection with oral olanzapine (HGLQ, ClinicalTri-
als.gov registration number NCT 00320489) [12]. Ethics
approval for the study was granted by the research com-
mittees of the participating centers following country reg-
ulations. All participants gave their informed consent prior
to inclusion. The study included 524 outpatients who met
diagnostic criteria for schizophrenia and were considered
to be at risk of relapse. Patients with DSM-IV- or DSM-IV-
TR-defined substance (except nicotine and caffeine)
dependence within the past 30 days were excluded from
the study. The study design consisted of two periods: a
screening phase during which the patients were screened
for eligibility (visits 1–2) and an open-label treatment
phase lasting up to 104 weeks. Patients were treated with
oral or long-acting injection during the course of the study.
Other antipsychotics, mood stabilizers, and anticonvulsants
were not allowed. Anticholinergics, antidepressants, except
fluvoxamine, which were started before study initiation,
and several benzodiazepines (up to a dose equivalent to
diazepam 30 mg/day) were allowed.
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Measures
Patients’ levels of functioning were assessed using the
following 5 measures: the Quality of Life Scale (QLS),
the Medical Outcomes Study Short Form-36 (SF-36), the
SOFI, the EuroQol-5 Dimensions Questionnaire (EQ-5D),
and patient productivity level.
The QLS [6] is an interviewer-rated scale used to assess
the health-related level of functioning in patients with
schizophrenia and includes while balancing subjective
questions regarding life satisfaction and objective indica-
tors of social and occupational role functioning. The QLS
is widely used in clinical trials of antipsychotic medica-
tions and in course of illness studies [13]. The QLS con-
sists of 21 items that are assessed during a semi-structured
interview. Completion requires approximately 45 min,
during which various topics are explored using specified
probes. Each item is rated on a 7-point (0–6) scale. High
numbers reflect normal or unimpaired functioning, and low
scores reflect severely impaired functioning. The range of
possible total score is 0–126 points. The scale contains 4
subdomains: intrapsychic foundations (e.g., degree of
motivation, scored from 0 = ‘‘Lack of motivation signifi-
cantly interferes with basic routine’’ to 6 = ‘‘No evidence
of significant lack of motivation’’), interpersonal relations
(e.g., level of social activity, scored from 0 = ‘‘virtually
absent’’ to 6 = ‘‘Adequate level of regular social activ-
ity’’), instrumental role (e.g., extent of occupational role
functioning, scored from 0=‘‘virtually no role functioning’’
to 6=‘‘full time or more’’), and common objects and
activities (e.g., time utilization, scored from 0 = ‘‘Spends
the vast majority of his/her day in aimless inactivity’’ to
6 = ‘‘No excessive aimless inactivity beyond the normal
amount required for relaxation’’). The QLS has been
shown to have acceptable psychometric qualities: Test–
retest reliability is good for nearly all items of the
scale, categories, and overall score. Internal consistency
alpha coefficients were 0.8–0.9 for the global score, and
convergent validity is good [14–16]. Cramer et al. [17]
reported that the QLS appeared to be substantially more
sensitive to subtle change and treatment effects than a
patient-reported QOL measure for clinical trials. Although
the QLS has been used extensively in schizophrenia
research, interpretation of the scale score has never been
clarified beyond stating that higher scores mean better
functioning. Due to lack of scale cutoff scores for various
levels of functioning, it is currently unclear which scores
may reflect patients’ ‘‘good,’’ ‘‘moderate,’’ or ‘‘poor’’ levels
of functioning.
The Medical Outcomes Study Short Form-36 (SF-36)
[18] is a patient-rated health status measure, one of the
most widely used QOL evaluation tool in the world to date.
It consists of 36 questions covering 8 areas of functioning
and well-being (physical function, bodily pain, role limi-
tations due to physical problems, vitality, general health
perceptions, role limitations due to emotional problems,
mental health, and social function). Each scale is linearly
transformed into a 0-100 scale with higher scores repre-
senting better health status and functioning. In addition to
scores for the 8 areas, there are 2 component scores, the
Mental Component Summary Score and Physical Compo-
nent Summary Score, in which the standardized scores
have a mean of 50 with a standard deviation of 10. These
component summary measures have features that make
them more advantageous for use in clinical trials, including
higher measurement precision, reduced floor and ceiling
effects, simpler analytic outcomes, and superior respon-
siveness [19]. The reliability and validity of the SF-36 in
the treatment of patients with schizophrenia has been pre-
viously studied, showing the SF-36 can be a reliable and
valid measure of perceived functioning and well-being for
schizophrenia patients [20]. In the current study, we
assessed patients’ mental health functioning using the
Mental Component Summary Score of the SF-36.
The SOFI [21] was developed to measure community
functioning and has four domains: (1) living situation,
(2) instrumental activities of daily living, (3) productive
activities, and (4) social functioning. Items from these
domains were scored by the participating investigators and
were combined to provide a global score, with higher
scores indicating a better level of functioning. The psy-
chometric properties of the SOFI have been studied [21],
showing good evidence supporting reliability and construct
validity. For example, the values for test–retest reliability
were[0.70, inter-rater reliability ICCs ranged from 0.50 to
0.79, and the SOFI demonstrated adequate construct
validity based on correlations with other QOL measures
like the QLS. Discriminant validity was also supported
based on SOFI score comparisons between patient groups
identified using PANSS scores.
The EuroQol-5 Dimensions Questionnaire (EQ-5D)
general tariff and visual analogue scale (EQ-5D VAS). The
EQ-5D is a generic questionnaire generating a health pro-
file and a single index score for health-related QOL. The
general tariff of the EQ-5D [22, 23] uses population norms
to transform a patient’s mean scores on the scale’s 5 items
(mobility, self-care, usual activities, pain/discomfort, and
anxiety/depression) into a single rating ranging from 0
(death) to 1 (best). The EQ-5D tariffs have been shown
to be stable across different European countries [24].
Furthermore, patients self-rated their current health status
using the EQ-VAS, on a scale that ranged from 0 (worst
imaginable health) to 100 (best imaginable health). The
validity of the EQ-5D in assessing and valuing health status
in patients with schizophrenia has been shown to be rea-
sonable, despite a moderate ceiling effect [25].
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Patient productivity level [26] was evaluated by the
participating investigator as measured by the percentage of
time the patient was involved in functional activities or
work (including work for pay, being a student, house-
keeping, and volunteer work) in the 3 months prior to
enrollment. This was assessed as a single item rated on a
5-point scale: (1) no useful functioning; (2) functional
activities occupied [0–25 % of the time; (3) functional
activities occupied [25–50 % of the time; (4) func-
tional activities occupied [50–75 % of the time; and
(5) functional activities occupied [75–100 % of the time.
The psychometric properties of this brief measure have not
been previously studied. Higher scores on this measure
were found [26] to be significantly associated with higher
study completion rates and better scores on the Positive and
Negative Symptom Scale (PANSS).
In addition to the measures of functioning, the patient
illness severity level was assessed with the Positive and
Negative Syndrome Scale, the PANSS [27], which is the
most widely used measure of symptom severity level in
schizophrenia research. The PANSS has 30 items, which
are rated on a scale from 1 (absent) to 7(extreme). The
PANSS scores are typically presented for the total scale
and separately for positive symptoms, negative symptoms,
and general psychopathology. Positive symptoms include
delusions, hallucinatory behavior, and suspicion/persecu-
tion, whereas negative symptoms include blunted affect,
emotional withdrawal, poor rapport, and passive/apathetic
social withdrawal. Symptoms of general psychopathology
include conceptual disorganization, disorientation, poor
attention, excitement, hostility, poor impulse control,
anxiety, and depression. The meaning of the PANSS total
scores has been previously delineated in an empirical
manner [10] where a total score of 58 corresponds to being
‘‘mildly ill,’’ a score of 75 to being ‘‘moderately ill,’’ a
score of 95 to ‘‘markedly ill,’’ and a PANSS score of 116 to
‘‘severely ill.’’ The psychometric properties of the PANSS
are currently well documented [28–30] showing good
validity and reliability. More recent studies have shown the
PANSS to have sound construct validity [31, 32], external
validity [33], and good internal consistency of its five-
factor structure, with Cronbach’s alpha [0.70 [31, 33].
Statistical analysis
Cluster definitions
Consistent with prior research [8], a hierarchical cluster
analysis based on Ward’s minimum-variance method was
used to define groups of patients using baseline values for the
QLS total score and the four QLS subscale scores, produc-
tivity levels, and SF-36 Mental Component Summary Score.
These variables were chosen since they evaluate functioning
and QOL. The clustering procedure was applied to stan-
dardized data. The number of clusters was chosen based on
the proportion of variation in the data (R2) captured by the
clusters; the decision was determined when a reduction in the
number of groups led to a substantial deterioration in R2.
Baseline socio-demographics and clinical characteristics
were described for each cluster.
Cluster validation
The construct validity of the three clusters (‘‘good,’’
‘‘moderate,’’ and ‘‘poor’’) was assessed using concurrent,
convergent, and divergent validity. Concurrent validity is
customarily assessed by comparing the results of a new
measure with results of a ‘‘gold standard’’ obtained at
approximately the same point in time, so that both mea-
sures reflect the same construct. Considering the absence of
a ‘‘gold standard,’’ this analysis assessed concurrent
validity by comparing the clusters with a theoretically
driven definition based on the QLS [9]. This approach
involved comparing the proportion of patients deemed to
have (as per Stahl et al.) ‘‘adequate psychosocial func-
tioning’’ in each of the newly identified functional level
clusters, where adequate psychosocial functioning for each
QLS subscale was defined as a baseline score C4 (‘‘at least
some consistent functioning’’) on all items within that QLS
subscale [9]. Another approach compared the clusters with
a previous, empirically driven criteria [8], which defined
‘‘good functioning’’ using scores on the QLS instrumental
and interpersonal domains and the productivity measure.
Convergent validity is typically determined by exam-
ining the overlap between two or more measures that are
presumed to assess the same construct. In this analysis,
convergent validity was assessed by comparing the func-
tional clusters using the EQ-5D scale (EQ-5D tariffs;
EQ-5D VAS scores; EQ-5D VAS [ 70) [34] and the SOFI
global scale scores.
Divergent validity examines the extent to which a
measure correlates with attributes that are different from
the attribute the measure is intended to assess; that is,
whether measures that should not be related are not. In this
analysis, divergent validity was assessed by looking for
associations between each of the functional clusters and
two parameters that are generally not expected to be related
to level of functioning: age and gender.
Analysis of differences between clusters
Statistical differences in variables between clusters were
assessed using analysis of variance for continuous variables
and chi-square tests for categorical variables
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Classification and regression tree analysis
Classification and regression tree (CART) analysis allows
the classification of patients into distinct groups based on
dichotomous criteria and was employed to define the rules
used to classify patients in the clusters [35]. The sensitivity
and specificity of the CART classification were calculated
to assess goodness of fit of the CART analysis.
Results
Baseline characteristics of the study sample
Baseline characteristics of the study sample are shown in
Table 1. More than two-thirds of the patients were male, and
the mean age was 40.9 years. The mean PANSS total score
was 56.7, indicating that patients were mildly ill [10]. Pro-
ductivity levels ranged from 0 % (no time involved in
functional activities) to 100 % of time involved in functional
activities, with the bulk of patients (roughly 60 %) spending
up to 50 % of their time involved in productive activities.
Cluster selection
Based on the proportion of variation in the data (R2) cap-
tured by the clusters, and determined when a reduction in
the number of groups led to a substantial deterioration in
R2, the number of clusters was chosen as three. Estimated
R2 for the two-cluster solution was 0.311, compared with
0.457 for the three-cluster solution, and 0.508 for four
clusters. The three-cluster solution was chosen to maximize
simplicity, explanatory power, and separation between the
groups. Figure 1 is a graphical representation of the three-
cluster solution; the bulk of the patients appears in cluster
2, flanked by smaller but roughly equal numbers of patients
in cluster 3 and cluster 1.
Cluster description
Baseline functional measure scores for patients in each of
the functioning clusters are shown in Table 2. As expected,
functioning (assessed using QLS total scores and scores
from the four QLS subscales) was highest in the good
cluster and deteriorated from ‘‘good’’ to ‘‘moderate’’ to
‘‘poor.’’ A similar pattern of deterioration from ‘‘good’’
through ‘‘moderate’’ to ‘‘poor’’ was seen for the SF-36
Mental Component Summary Score (indicating general
mental health status) and productivity levels. The bulk of
the patients were in the ‘‘moderate’’ functioning cluster,
with fewer (roughly equal numbers of) patients in the
‘‘good’’ and ‘‘poor’’ clusters.
Baseline patient characteristics by level of functioning
are shown in Table 3. The percentage of male patients,
mean age, age at illness onset, and illness duration
appeared to be roughly similar across the clusters. Symp-
tom severity according to PANSS total score, negative and
Table 1 Baseline characteristics of the study sample
Characteristic
Male gender, n (%) 352 (67.2)
Age, years 40.9 (10.9)
Age at illness onset, years 26.2 (8.9)
Illness duration, years 14.8 (10.5)
PANSS total score 56.7 (9.3)







QLS total score 63.1 (20.1)
QLS common objects and activities 6.6 (2.6)
QLS intrapsychic foundation 21.8 (7.4)
QLS interpersonal relations 20.5 (9.6)
QLS instrumental role 14 (3.4)
SOFI global score 60.6 (18.4)
EQ-5D VAS score 66.9 (23.2)
EQ-5D general tariff score (1–5) 0.7 (0.3)
SF-36 Mental Component Summary
Score mental composite score
41.2 (11.5)
Data are presented as mean (SD) unless indicated otherwise
EQ-5D EuroQol-5 Dimensions Questionnaire, PANSS Positive and
Negative Symptom Scale, QLS Quality of Life Scale, SF-36 Medical
Outcomes Study Short Form-36, SOFI Schizophrenia Objective
Functioning Scale, SD standard deviation, VAS visual analogue scale
Fig. 1 Graphical presentation of the three-cluster solution: cluster
1 = ‘‘moderate’’ functioning, cluster 2 = ‘‘poor’’ functioning, and
cluster 3 = ‘‘good’’ functioning. [For color reproduction]
Qual Life Res (2013) 22:2085–2094 2089
123
general psychopathology subscale scores (P \ 0.0001) and
PANSS positive subscale score (P \ 0.01) was signifi-
cantly different across the three clusters; symptom severity
was best (lowest) in the ‘‘good’’ functioning cluster and
worst in the ‘‘poor’’ functioning cluster. Productivity levels
were significantly different across the three clusters
(P \ 0.0001) and were highest in the ‘‘good’’ functioning
cluster and lowest in the ‘‘poor’’ functioning cluster;
25.3 % of patients in the ‘‘good’’ functioning cluster and
0 % of patients in the ‘‘poor’’ functioning cluster had
[75–100 functional activities in the last 3 months, and
3.2 % of patients in the ‘‘good’’ functioning cluster and
42.7 % of patients in the ‘‘poor’’ functioning cluster had no
functional activities in the 3 months prior to enrollment.
There were no differences in distribution of patients in each
of the clusters for each treatment group.
Pairwise comparisons revealed that there were signifi-
cant differences between the ‘‘good’’ and ‘‘moderate’’
clusters, and between the ‘‘good’’ and ‘‘poor’’ clusters in
PANSS total, negative, positive, and general psychopa-
thology subscale scores, and in the proportion of patients
with no functional activities (Table 3). There were signif-
icant differences between the ‘‘moderate’’ and ‘‘poor’’
clusters only in PANSS total and negative subscale scores
and in the proportion of patients with no functional
activities.
Table 2 Baseline functional
measure scores by functioning
cluster
Data are presented as mean
(SD)
QLS Quality of Life Scale,
SF-36 Medical Outcomes Study
Short Form-36, SD standard
deviation
Functional measure ‘‘Good’’ ‘‘Moderate’’ ‘‘Poor’’
QLS total score 93.5 (8.8) 61.9 (10.7) 37.3 (7.6)
QLS common objects and activities 9.4 (1.5) 6.6 (1.9) 3.6 (1.6)
QLS intrapsychic foundation 31.7 (3.6) 21.8 (4.5) 11.9 (3.5)
QLS interpersonal relations 34.0 (6.2) 19.7 (6.4) 10.1 (4.8)
QLS instrumental role 18.2 (2.8) 13.5 (2.8) 11.7 (2.2)
SF-36 Mental Component Summary Score 44.4 (10.0) 41.1 (11.5) 38.4 (12.4)
Productivity level 3.5 (1.2) 2.7 (1.0) 1.6 (0.6)
Number of patients 95 321 96
Table 3 Baseline patient characteristics by level of functioning










Number of patients 95 321 96
Male gender, n (%) 60 (63.2) 218 (67.9) 66 (68.8) 0.3872 0.4148 0.8773
Age, years 39.2 (10.9) 41.1 (10.9) 42.0 (10.6) 0.1895 0.0745 0.3499
Age at illness onset, years 26.1 (8.5) 26.1 (8.9) 27.1 (9.4) 0.9533 0.5170 0.4509
Illness duration, years 13.1 (10.4) 15.0 (10.4) 14.9 (10.1) 0.0683 0.1257 0.9019
PANSS total score* 51.1 (10.6) 57.1 (8.4) 59.9 (8.3) \0.0001 \0.0001 0.0014
PANSS negative subscale score* 14.2 (3.9) 15.9 (4.0) 17.8 (3.7) 0.0018 \0.0001 \0.0001
PANSS positive subscale score** 11.7 (3.7) 12.9 (3.4) 12.8 (3.5) 0.0022 0.0270 0.7090
PANSS general psychopathology score* 25.2 (5.6) 28.3 (4.8) 29.3 (5.3) \0.0001 \0.0001 0.1086
Proportion of patients in each productivity level, %*
0 3.2 9 42.7 \0.0001 \0.0001 \0.0001
[0–25 22.1 34.6 54.2
[25–50 17.9 33.0 3.1
[50–75 31.6 21.2 0.0
[75–100 25.3 2.2 0.0
Data are presented as mean (SD) unless indicated otherwise
SD standard deviation, PANSS Positive and Negative Symptom Scale
Significant differences across the three levels of functioning: * P \ 0.0001; ** P \ 0.01




Concurrent validity (i.e., the proportion of patients with
‘‘adequate psychosocial functioning’’) across the three
clusters was ‘‘good’’; the proportion of patients with ade-
quate psychosocial functioning in all QLS subscales was
greatest in the ‘‘good’’ functioning cluster, intermediate in
the ‘‘moderate’’ functioning cluster, and lowest in the
‘‘poor’’ functioning cluster (Table 4) (P \ 0.0001 for dif-
ferences across the three levels of functioning). For
example, 60.0 % of patients in the ‘‘good’’ functioning
cluster fulfilled the criteria for adequate intrapsychic
foundation, while only 2.5 % of patients in the ‘‘moderate’’
functioning cluster and 0 % of patients in the ‘‘poor’’
functioning cluster fulfilled this criterion.
Based on the second approach (i.e., the proportion of
patients meeting empirically defined criteria that included
functioning and symptom severity), pairwise comparisons
revealed significant differences between the ‘‘good’’ and
‘‘moderate’’ clusters, and between the ‘‘good’’ and ‘‘poor’’
clusters in the four QLS subscales and the empirically
defined criteria by Lipkovich et al. [8] (Table 4). There
were significant differences between the ‘‘moderate’’ and
‘‘poor’’ clusters only in the QLS subscales of instrumental
role and common objects and activities, and empirically
defined criteria.
Convergent validity
Convergent validity (assessed by comparing the clusters
using the EQ-5D scale and SOFI scale scores) was ‘‘good’’;
mean SOFI global scores and EQ-5D general score tariffs
were highest in the ‘‘good’’ functioning cluster, interme-
diate in the ‘‘moderate’’ functioning cluster, and lowest in
the ‘‘poor’’ functioning cluster (Table 5) (P \ 0.0001 for
differences across the three levels of functioning). Mean
EQ-5D VAS scores and the percentage of patients with
EQ-VAS scores [70 were also highest in the ‘‘good’’
Table 4 Concurrent validity; the proportion of patients in the ‘‘good,’’ ‘‘moderate,’’ and ‘‘poor’’ functional clusters with an adequate level of
functioning for each QLS subscale and according to the empirical definition of functioning







QLS subscale (Stahl et al. [7])
Adequate intrapsychic foundation* 57 (60.0) 8 (2.5) 0 (0.0) \0.0001 \0.0001 0.2070
Adequate interpersonal relations* 34 (35.8) 2 (0.6) 0 (0.0) \0.0001 \0.0001 1.0000
Adequate instrumental role* 49 (51.6) 17 (5.3) 0 (0.0) \0.0001 \0.0001 0.0166
Adequate common objects/activities* 87 (91.6) 108 (33.6) 2 (2.1) \0.0001 \0.0001 \0.0001
Empirically defined criteria
(Lipkovich et al. [6])*
91 (95.8) 196 (61.1) 31 (32.3) \0.0001 \0.0001 \0.0001
Data are presented as number (%)
QLS Quality of Life Scale
Significant differences across the three levels of functioning: * P \ 0.0001
Table 5 Convergent validity; comparisons between the functional clusters using measures that are presumed to assess the same construct—the
SOFI and the EQ-5D scale







SOFI global score* 78.2 (12.9) 61.7 (14.3) 39.7 (14.6) \0.0001 \0.0001 \0.0001
EQ-5D general score
tariff*
0.84 (0.16) 0.72 (0.27) 0.61 (0.37) 0.0002 \0.0001 0.0131
EQ-5D VAS** 71.4 (21.1) 66.0 (22.1) 64.2 (28.2) 0.0128 0.0977 0.6992
EQ-5D VAS score
[70**
54.3 39.7 38.3 0.0121 0.0282 0.8084
Data are presented as mean (SD) or %
SOFI Schizophrenia Objective Functioning Scale, EQ-5D EuroQol-5 Dimensions Questionnaire, VAS visual analogue scale
Significant differences across the three levels of functioning: * P \ 0.0001; ** P \ 0.05
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functioning cluster, intermediate in the ‘‘moderate’’ func-
tioning cluster, and lowest in the ‘‘poor’’ functioning
cluster (P \ 0.05 for differences across the three levels of
functioning).
Pairwise comparisons revealed that there were signifi-
cant differences between the ‘‘good’’ and ‘‘moderate’’
clusters in all measures (SOFI global score, EQ-5D general
score tariff, EQ-5D VAS, and EQ-5D VAS score [70)
(Table 5). There were significant differences between the
‘‘good’’ and ‘‘poor’’ clusters in SOFI global score, EQ-5D
general score tariff, and the EQ-5D VAS score[70, but not
the EQ-5D VAS. There were significant differences
between the ‘‘moderate’’ and ‘‘poor’’ clusters only in SOFI
global score and EQ-5D general score tariff.
Divergent validity
The divergent validity of the clusters (assessed by looking
for associations between the clusters and parameters that
should not be related) was ‘‘good,’’ as shown by the lack of
significant differences between the clusters on age and
gender (Table 3).
Classification and regression tree analysis
CART analysis defined cutoff points to classify the patients
into the three clusters. Patients with a QLS total score
[84.5 were classified as having ‘‘good’’ functioning,
whereas ‘‘moderate’’ and ‘‘poor’’ functioning were sepa-
rated by a cutoff score of 15.5 on the QLS intrapsychic
foundation domain (Fig. 2). Using this definition of clus-
ters, compared with the empirically defined criteria, sen-
sitivity ranged from 86 to 93 % and specificity ranged from
89 to 99 %.
Discussion
This study presents an empirical classification of patients
with schizophrenia based on their level of functioning that
helps us understand what given scores on a commonly used
functional measure (the QLS) mean in clinical practice,
and thus aids the translation of research findings into
clinical practice. Improving a patient’s level of functioning
is an important aim of the treatment, as symptom improve-
ment is no longer considered a sufficient goal in the long-
term treatment of patients with schizophrenia [36]. ‘‘Poor’’
levels of functioning were previously found to be related to
patient QOL [37] and to treatment cost [38] and thus are of
importance not only to patients and their family members,
but also to mental health providers, health care decision
makers and payers.
To our knowledge, this is the first study to empirically
delineate the meaning of functional measure scores in the
treatment of patients with schizophrenia. Although one
prior study used a theoretically or consensus-based classi-
fication of patient functioning [9], and another study [8]
used an empirically driven classification incorporating
symptoms and functioning, to our knowledge, no previous
study has used an empirically driven classification of
functional measures alone. For the validation of the new
clusters, and in the absence of a ‘‘gold standard,’’ we used
prior definitions of functional levels from these two pre-
vious studies to assess the construct validity of the new
classification of ‘‘good,’’ ‘‘moderate,’’ and ‘‘poor’’ levels of
functioning.
Consistent with our hypothesis, patients with a ‘‘good’’
level of functioning had a significantly lower severity level
of schizophrenia symptoms, greater levels of productive
activity, and higher scores on other health-related QOL
measures. This differentiation was consistently observed
when using patient self-reported measures (SF-36 and
EQ-5D) or a clinician-rated scale (SOFI), demonstrating the
robustness and the utility of patient-reported health-related
outcomes even when reported by persons diagnosed with
and treated for a psychotic disorder like schizophrenia. Our
finding of a significant link between a patient’s level of
functioning and their level of illness severity per PANSS
scores is also consistent with prior research [39–42]. This
link was found despite the fact that the study participants
were only mildly ill, and differentiation on illness severity
levels among mildly ill patients is typically difficult (the
‘‘floor effect’’). Nonetheless, the new classification of
levels of functioning was sufficiently sensitive to detect
minor gradations of PANSS scores in the mildly ill range,
with a mean PANSS total score of 51, 57, and 60 linked to
‘‘good,’’ ‘‘moderate,’’ and ‘‘poor’’ levels of functioning,
respectively.
Current findings have also supported another study
hypothesis that differentiation between patients’ levels of
functioning on the QLS will be best accomplished not only
by the total score on the scale, but by also incorporating
patients’ drive, sense of purpose and motivation. This wasFig. 2 Classification and regression tree (CART) analysis
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demonstrated in the CART analysis, which identified cutoff
points to classify patients into the three clusters and
found—with a high level of sensitivity and specificity
(sensitivity ranged from 86 to 93 % and specificity ranged
from 89 to 99 %)—that differentiation was maximized
when using the QLS total score and the QLS intrapsychic
foundation domain, which measures patients’ drive and
motivation. Thus, when using the QLS, patients with a total
score[84.5 were classified as having ‘‘good’’ functioning,
whereas ‘‘moderate’’ and ‘‘poor’’ functioning were sepa-
rated by a cutoff score of 15.5 on the QLS intrapsychic
foundation domain. Moreover, in the process of validating
the new clusters (convergent validity), this study has also
identified what ‘‘good,’’ ‘‘moderate,’’ and ‘‘poor’’ levels of
functioning (per QLS) corresponded to on two other
functional measures: a generic measure (EQ-5D) and a
disease-specific measure (SOFI), demonstrating that the
current findings may be of utility beyond the QLS, in
clinical or research settings where these other health-rela-
ted QOL measures are being used. Overall, the construct
validation of the three functional levels (per concurrent,
convergent, and divergent validity) suggests that the
resulting classification is valid, showing consistent and
statistically significant differentiation between the clusters
in the expected direction.
This study found that approximately 60 % of the
patients were classified as having a ‘‘moderate’’ level of
functioning, while a smaller proportion was classified as
having either a ‘‘good’’ or a ‘‘poor’’ level of functioning
(20 % each). This distribution of functional clusters should
not be generalized to other patients with schizophrenia, as
it is specific to the patient population enrolled in the study.
One should expect heterogeneity among schizophrenia
patients on their levels of functioning, and these levels are
likely to shift over time, across phases of the illness, and
differ between patients observed in usual clinical settings
as compared to controlled clinical trials.
Limitations
Several limitations need to be considered when interpreting
the results of this analysis. Firstly, study participants were
only mildly ill; thus, it is unclear whether the current
findings can be generalized to patients with more severe
levels of symptoms. Secondly, as this was a cross-sectional
study, the predictive validity of the functional definitions
was not assessed. Third, divergent validity was only
assessed by comparing gender, age, and age of onset of the
three clusters, but comparison has been made with a scale
measuring a different constructs. Finally, as this analysis
was conducted in a patient population participating in a
randomized clinical trial, the classification of functioning
will require replication in schizophrenia patients treated in
the usual care setting.
Conclusion
The substantial heterogeneity in levels of functioning
among schizophrenia patients can be reliably classified in
an empirical manner using specific cutoff scores on a
commonly used functional measure, the QLS. Validity
assessment of the classes and classification method has
been shown to be ‘‘good.’’ While further research is needed
to replicate these results, the current findings have utility in
the translation of assessment scales into relevant clinical
categories.
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